Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Azimuth Capital Investment Management LLC

Azimuth Capital Investment Management LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,141 shares of the pharmaceutical company's stock after buying an additional 697 shares during the period. Azimuth Capital Investment Management LLC's holdings in Vertex Pharmaceuticals were worth $8,916,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Brown Lisle Cummings Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth $30,000. Sugar Maple Asset Management LLC purchased a new position in Vertex Pharmaceuticals in the 4th quarter valued at about $35,000. Golden State Wealth Management LLC acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth approximately $37,000. Truvestments Capital LLC grew its holdings in shares of Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after buying an additional 23 shares in the last quarter. Finally, Midwest Capital Advisors LLC purchased a new position in Vertex Pharmaceuticals in the 4th quarter worth approximately $41,000. Institutional investors own 90.96% of the company's stock.

Analysts Set New Price Targets

VRTX has been the subject of several analyst reports. Bank of America increased their price objective on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. Piper Sandler decreased their target price on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and boosted their price target for the company from $408.00 to $424.00 in a research note on Tuesday, February 11th. Truist Financial increased their price objective on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Finally, Scotiabank increased their price target on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a research report on Tuesday, February 11th. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $512.41.

Remove Ads

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 530 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the completion of the sale, the executive vice president now directly owns 58,539 shares in the company, valued at $27,825,928.26. This represents a 0.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the transaction, the executive vice president now owns 26,512 shares in the company, valued at $13,256,000. The trade was a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,315 shares of company stock valued at $2,121,012 over the last three months. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock traded up $8.43 on Monday, reaching $492.65. 381,415 shares of the stock were exchanged, compared to its average volume of 1,322,366. The firm has a market capitalization of $126.51 billion, a PE ratio of -223.93, a PEG ratio of 2.11 and a beta of 0.50. The business has a fifty day moving average price of $484.84 and a two-hundred day moving average price of $464.28. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.